In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH.
His abstract entitled ‘Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.
Please view Part 1 for information on the mechanism of action of icosabutate.
Disclosures: Prof Arun Sanyal has acted as an advisor/board member for Gilead; a consultant for 89 BIO, Affimune, Albireo, Allergan, AMRA, Ardelyx, BASF, Birdrock, Boehringer Ingelheim, Bristol Myers Squibb, Chemomab, Conatus, Durect, Echosans, Enyo, Fractyl, Galectin, General Electric, Genfit, Gilead Hemoshear, Immuron, Indalo, Intercept, Janssen, Lilly, Malinckrodt, Merck, Nimbus, Novartis, Northsea, Novo Nordisk, Perspectum, Pfizer, Poxel, Salix, Sanofi, Second Genome, Servier, Takeda, Terns, Teva, Zydus; received grant/research support from Bristol-Myers Squibb, Conatus, Echosans, Galectin, Gilead, Lilly, Malinckrodt, Merck, Novartis, Novo Nordisk, Fractyl, Madrigal, Inventiva, Covance and Sequana; has stockholder/ownership interest (excluding diversified mutual funds) in Akarna, Durect, Exhalenz, Genfit, Hemoshear, Indalo, Tiziana; is PI for an ongoing trial sponsored by Genfit; has provided advice (no remuneration) to BASF, Galectin, Immuron and has received Royalties from Elsevier and UpToDate.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Sven Francque, EASL ILC 2021: Lanifibranor NATIVE Subgroup Analysis
Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH. His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a […]
Sven Francque, EASL ILC 2021: Subgroup Analysis of Semaglutide in NASH
It was a pleasure to speak with Prof. Dr Sven Francque (University of Antwerp, Belgium) about the recent post-hoc analysis of the phase 2 trial of semaglutide in patients with NASH. The analysis was designed to assess whether patient and disease characteristics influenced the effect of the drug on the resolution of NASH. His abstract […]
Kenneth Cusi, EASL ILC 2021: First-in-class AMP-Kinase Activator, PXL770, in NASH
It was an absolute pleasure to speak with Dr Kenneth Cusi (University of Florida, Gainesville, FL, USA) about the novel compound PXL770 and the results of the STAMP-NAFLD phase 2 trial investigating its potential in NASH. His abstract entitled ‘Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!